2 Result: Nasdaq:TARS
Buy Ratings: TARS, VICR, SNDX, ENLC, AMZN, UFPT, PEN - Key Upside Potential
June 26th, 2023
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. $TARS closed at $17.15. Read more
Market Buzz: Bullish Narrative for Liquid Media, Tarsus Pharma, Vertiv, and Neogen
June 17th, 2023
Shares of Liquid Media Group Ltd. (Nasdaq: YVR) experienced a notable surge of over 11% in after-hours trading Friday as the company revealed the sale of its wholly-owned subsidiary, IndieFlix Group, for a total purchase price of US$1.2 million. T. Read more
Want To Find Some News?
News By Industries
Recent Post
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login